News

The Novartis Venture Fund was also a seed investor in the company. BCCC Avocats acted as counsel to the investors and BMP Associes acted as counsel to the

The trial is ongoing with over 130 specialist HIV centers in 15 countries and results from this component of the trial are expected in the second quarter of

The Phase I trials were both double-blind, placebo-controlled, dose escalation studies designed to evaluate the safety, tolerability and pharmacokinetics of SD118 administered in an oral formulation. In the

Data were reported from the single-arm, single-agent study of dacetuzumab in 46 patients with diffuse large B-cell lymphoma (DLBCL). Patients were heavily pre-treated, with a median of four

A total of 50 patients with non-Hodgkin lymphoma were treated on the open label single-arm, dose-escalation study of SGN-40. Cohorts of patients received escalating doses of SGN-40 ranging

The study also compared a sequential combination of the two agents versus allopurinol alone, which showed a reduction in plasma uric acid levels for the sequential combination versus

This will be the last clinical trial conducted for submission of the new drug application (NDA) to the State Food and Drug Administration in China. Rhei licensed Tibozole

Under the expanded access program, children two months to 17 years in age inclusive with Grades B-D acute graft versus host disease (GVHD) not responsive to steroids are

The company has reported results from two identically designed, randomized, double blind, placebo-controlled global studies. Patients with an established diagnosis of uncontrolled partial onset seizures (POS) for one